Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

8.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

827
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
827
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhalational therapy of pulmonary infection <i>via</i> macrophage-targeted nanoemulsions.

Acta pharmaceutica Sinica. BĀ·2026
Same author

Current trends and future directions of artificial intelligence in lung cancer diagnosis.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiuĀ·2026
Same author

NLRP3 and CCR1 drive offspring asthma susceptibility following maternal RSV infection.

International immunopharmacologyĀ·2026
Same author

Expanding role of cell-free DNA for the early diagnosis and monitoring of pulmonary diseases.

Chinese medical journalĀ·2026
Same author

Immune dysregulation triggered by inflammatory cytokines in patients with severe respiratory infections.

Respiratory researchĀ·2026
Same author

A Dichloropropionamide-Substituted Diaminopyrimidine EGFR-TKI Overcomes Osimertinib Resistance in NSCLC via Dual Anchoring at Ser797 and Met793.

Journal of medicinal chemistryĀ·2025

Related Experiment Video

Updated: Aug 7, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

RSK inhibitors as potential anticancer agents: Discovery, optimization, and challenges.

Ying Sun1, Lichao Tang2, Chengyong Wu3

  • 1Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

European Journal of Medicinal Chemistry
|March 10, 2023
PubMed
Summary

Ribosomal S6 kinase (RSK) inhibitors show promise for cancer therapy but face challenges. Future drug development must prioritize selectivity among RSK isoforms for improved efficacy and clinical translation.

Keywords:
CancerInhibitorsRSKStructure-activity relationship

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Experiment Videos

Last Updated: Aug 7, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Ribosomal S6 kinase (RSK) is a key effector in the Ras-MAPK pathway, regulating cell growth and proliferation.
  • RSK plays a significant role in cancer development, making it a potential therapeutic target for anti-cancer and anti-resistance strategies.

Purpose of the Study:

  • To review RSK inhibitors, their structural optimization, and their association with various cancers.
  • To highlight the importance of RSK isoform selectivity in future drug development for enhanced therapeutic outcomes.

Main Methods:

  • Literature review of published studies on RSK inhibitors.
  • Analysis of structural characteristics and optimization processes of RSK inhibitors.
  • Discussion of cancer types associated with RSK and future directions in drug design.

Main Results:

  • Several RSK inhibitors have been developed, but only two have reached clinical trials due to issues like low specificity and poor pharmacokinetics.
  • Structure optimization strategies have focused on improving RSK interaction, stability, and binding site adaptation.
  • Functional differences among RSK isoforms necessitate a shift towards developing selective inhibitors.

Conclusions:

  • RSK inhibitors hold therapeutic potential, but overcoming limitations in specificity and selectivity is crucial.
  • Future research should focus on designing RSK inhibitors with high potency, specificity, and isoform selectivity for effective cancer treatment.